South Korean medical AI company Coreline Soft has obtained medical device certifications from Singapore's Health Sciences Authority for its line of AI diagnostic support solutions.

Founded in 2012, the company develops AI imaging diagnosis solutions, specialising in thoracic disorders. 

It gained approvals from Singapore's HSA for the following nine software solutions: 

• AVIEW LCS, an AI-based automatic pulmonary nodule analysis solution;
• AVIEW COPD, an automatic analysis solution for chronic obstructive pulmonary disease;
• AVIEW CAC, a coronary artery calcification automatic diagnosis solution;
• AVIEW Modeler, a medical image 3D modeling and printing solution;
• AVIEW Lung Texture, a fully automatic interstitial lung disease pattern analysis solution;
• AVIEW RT ACS, a fully automatic organ segmentation solution;
• Fissure Integrity, a fissure analysis solution; and
• Q-Infect, an automatic analysis solution for infectious lung diseases for COVID-19. 

WHY IT MATTERS

Coreline Soft has been aggressively expanding in recent years by persistently securing multiple regulatory approvals abroad as it seeks to take on the global healthcare AI market, which is projected to be worth $188 billion by 2030. 

This also comes as its flagship product AVIEW LCS has increasingly proven its value in national lung cancer screening projects across Europe. Moreover, some major hospitals in Taiwan, Germany, Belgium and Italy have also adopted the same AI solution.

THE LARGER TREND

This latest regulatory win follows Coreline Soft's market approvals in the United States, Europe, Japan, and Taiwan. Early this year, it received a three-year clearance from the Medical Device Single Audit Program.

Additionally, Coreline Soft is this year's only Asian participant in GE Healthcare's Edison Accelerator Program, which is expediting, validating, and scaling health AI Solutions.